Form D · Biotechnology
Hubble Therapeutics, LLC
Hanover, NH · CIK 0002038883
Offering snapshot reported Oct 21, 2024 · SEC filing
- Reported sold
- $9.81M Offering amount: $11.1M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 9, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2024 | Initial | $9,807,697 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-527330
Source: Form D, filed Oct 21, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sam Goldberger | Director |
| Greg Keenan | Director |
| Jeff Sabados | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
35 South Main Street
Hanover, NH, 03755
Hanover, NH, 03755